Corcept Therapeutics (NASDAQ:CORT) will be announcing its earnings results after the market closes on Tuesday, August 4th. Analysts expect the company to announce earnings of $0.20 per share for the quarter. Corcept Therapeutics has set its FY 2020
After-Hours guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link.
Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Monday, May 4th. The biotechnology company reported $0.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.03. Corcept Therapeutics had a return on equity of 30.00% and a net margin of 31.64%. The business had revenue of $93.25 million during the quarter, compared to analysts’ expectations of $87.01 million. During the same quarter last year, the business posted $0.20 earnings per share. The company’s quarterly revenue was up 43.8% on a year-over-year basis. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of CORT stock opened at $14.95 on Friday. The stock has a 50-day simple moving average of $16.35 and a 200 day simple moving average of $13.76. Corcept Therapeutics has a fifty-two week low of $9.70 and a fifty-two week high of $18.52. The stock has a market capitalization of $1.71 billion, a P/E ratio of 16.99 and a beta of 1.15.
Several research analysts recently weighed in on CORT shares. BidaskClub cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. ValuEngine lowered Corcept Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 2nd. Zacks Investment Research lowered Corcept Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price target for the company. in a research report on Tuesday, June 23rd. Finally, TheStreet upgraded Corcept Therapeutics from a “c+” rating to a “b-” rating in a research report on Tuesday, May 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $18.25.
About Corcept Therapeutics
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.